Tempest Therapeutics, Inc. — Director's Dealing 2018

Dec 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: Lillie James Woodruff (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-10	Employee Stock Option (right to buy)	$13.98	A	8333	Acquired	2028-05-10	Common Stock (8333)	Direct

Footnotes

F1: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F2: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause).